Triveni Bio
Phase 2Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $104M
About
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
AntibodiesBiologics
Funding History
2Total raised:$104M
Series A$92MOct 15, 2022
Seed$12MMay 15, 2021